Veristat Congratulates Origin Biosciences for FDA Approval of Nulibry During the Week of Rare Disease Day 2021
Veristat , a scientific-minded, global clinical research organization (CRO), today congratulated Origin Biosciences for their FDA approval of Nulibry (fosdenopterin) for injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A. This rare disease product received FDA approval on Friday, 26 February 2021, during the week when the world celebrated #RareDiseaseDay2021.
Veristat’s biostatisticians, programmers, and medical writers collaborated with Origin Biosciences to support the New Drug Application (NDA) for Nulibry. The entire Veristat team is honored to know that the hard work and perseverance of the combined Origin/Veristat team brought new hope for children whose lives are shortened by the devastating disease MoCD Type A.
“We thank the entire Veristat team who worked diligently to help us bring this critical therapy to patients with no other FDA-approved treatment options,” said Dr. Liza Squires, Origin Chief Medical Officer.
“Knowing that our work makes a difference in the lives of patients and their families around the world is the driving force of Veristat,” stated Patrick Flanagan, Chief Executive Officer at Veristat. “Origin Biosciences offers hope to pediatric patients and their families who now have a first-of-its-kind therapy to extend life. I congratulate and thank everyone involved in this momentous achievement of bringing Nulibry to market. I cannot think of a better way to celebrate and culminate the week of Rare Disease Day 2021.”
Helping clients to commercialize more treatments for rare diseases is an evergreen goal at Veristat. We understand that nothing is standard when developing a therapy for a rare or ultra-rare disease. Every step of the clinical development and approval process is more complicated. That is why we have assembled a scientific-minded team of experts who have supported nearly 600 clinical programs and prepared more than 70 marketing applications for rare disease treatments and cures.
Veristat , a global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 26 years’ experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared over 100 marketing applications for approval with global regulatory authorities in the last 10 years.
Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. We apply this knowledge base every day to solve any clinical program's challenges, from the simplest to the most complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives. For more information, visit www.veristat.com .
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-C3.AI12.4.2021 09:02:09 CEST | Press release
Yokogawa Selects C3 AI Suite to Enhance Enterprise AI Applications
TITOMIC12.4.2021 09:02:08 CEST | Press release
Titomic & Néos to Manufacture Invar36 Faceplates in the UK
IHS-TOWERS12.4.2021 08:02:13 CEST | Press release
IHS Towers Announces Further Latin America Expansion Through Centennial Towers Acquisition
VALBIOTIS12.4.2021 07:37:11 CEST | Press release
Valbiotis Reveals Positive TOTUM•854 Preclinical Results in the Prevention of Hypertension at the Annual ESH-ISH Joint Meeting
INMOBI12.4.2021 06:02:07 CEST | Press release
stc pay with UM MENA and InMobi Wins Four Awards at MMA SMARTIES MENA 2020
UNICONTROL12.4.2021 06:02:07 CEST | Press release
World First From Unicontrol: Bespoke 3D Machine Control for Backhoe Operation
DC-EIG9.4.2021 22:32:12 CEST | Press release
EIG Signs $12.4 Billion Infrastructure Deal with Aramco
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom